uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
Reg Canc Ctr South East Sweden, Linkoping, Sweden.;Linkoping Univ, Dept Clin & Expt Med, Oncol, Fac Hlth Sci, Linkoping, Sweden..
Linkoping Univ, Dept Clin & Expt Med, Oncol, Fac Hlth Sci, Linkoping, Sweden..
Umea Univ Hosp, Dept Oncol, Umea, Sweden..
Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden..
Show others and affiliations
2017 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 56, no 4, 614-617 p.Article in journal (Refereed) Published
Abstract [en]

Background: Tamoxifen is a well established treatment for breast cancer, but its long-term effects on the incidence of secondary cancers are not fully evaluated.Material and methods: We have studied 4128 postmenopausal patients with early stage breast cancer who were alive and free of breast cancer recurrence after two years of tamoxifen, and who were randomized to receive totally two or five years of therapy.Results: Compared to patients randomized to two years of tamoxifen the incidence of contralateral breast cancer [hazard ratio (HR) 0.73; 95% CI 0.56-0.96] and of lung cancer (HR 0.45; 95% CI 0.27-0.77), especially squamous cell and small cell lung cancer, were reduced in the five-year group, and similar results were seen when restricting the analysis to the 10-year period after treatment stopped. An increased incidence of endometrial cancer was observed in the five-year group, but the excess risk decreased over time.Conclusion: Further studies of the effects of tamoxifen on the risk of different histological types of lung cancer are needed.

Place, publisher, year, edition, pages
Taylor & Francis, 2017. Vol. 56, no 4, 614-617 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-322232DOI: 10.1080/0284186X.2016.1273547ISI: 000399499600016PubMedID: 28080180OAI: oai:DiVA.org:uu-322232DiVA: diva2:1096348
Available from: 2017-05-17 Created: 2017-05-17 Last updated: 2017-05-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindman, Henrik
By organisation
Experimental and Clinical Oncology
In the same journal
Acta Oncologica
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 226 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf